The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
Open accessAbstract
BACKGROUND: The relative efficacy and safety of intravitreous aflibercept, bevacizumab, and ranibizumab in the treatment of diabetic macular edema are unknown. METHODS: At 89 clinical sites, we randomly assigned 660 adults (mean age, 61±10 years) with diabetic macular edema involving the macular center to receive intravitreous aflibercept at a dose of 2.0 mg (224 participants), bevacizumab at a dose of 1.25 mg (218 participants), or ranibizumab at a dose of 0.3 mg (218 participants). The study drugs were administered as often as every 4 weeks, according to a protocol-specified algorithm. The primary outcome was the mean change in visual acuity at 1 year. RESULTS: From baseline to 1 year, the mean visual-acuity letter score (range, 0 to 100, with higher scores indicating better visual acuity; a score of 85 is approximately 20/20) improved by 13.3 with aflibercept, by 9.7 with bevacizumab, and by 11.2 with ranibizumab. Although the improvement was greater with aflibercept than with the other two drugs (P<0.001 for aflibercept vs. bevacizumab and P=0.03 for aflibercept vs. ranibizumab), it was not clinically meaningful, because the difference was driven by the eyes with worse visual acuity at baseline (P<0.001 for interaction). When the initial visual-acuity letter score was 78 to 69 (equivalent to approximately 20/32 to 20/40) (51% of participants), the mean improvement was 8.0 with aflibercept, 7.5 with bevacizumab, and 8.3 with ranibizumab (P>0.50 for each pairwise comparison). When the initial letter score was less than 69 (approximately 20/50 or worse), the mean improvement was 18.9 with aflibercept, 11.8 with bevacizumab, and 14.2 with ranibizumab (P<0.001 for aflibercept vs. bevacizumab, P=0.003 for aflibercept vs. ranibizumab, and P=0.21 for ranibizumab vs. bevacizumab). There were no significant differences among the study groups in the rates of serious adverse events (P=0.40), hospitalization (P=0.51), death (P=0.72), or major cardiovascular events (P=0.56). CONCLUSIONS: Intravitreous aflibercept, bevacizumab, or ranibizumab improved vision in eyes with center-involved diabetic macular edema, but the relative effect depended on baseline visual acuity. When the initial visual-acuity loss was mild, there were no apparent differences, on average, among study groups. At worse levels of initial visual acuity, aflibercept was more effective at improving vision. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT01627249.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
(2007) · Developments in Ophthalmology · doi:10.1159/isbn.978-3-318-01439-6 · Cited by 5,583
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Schafer, J. L. (1999) · Statistical Methods in Medical Research · doi:10.1177/096228029900800102 · Cited by 3,949
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Easy SAS Calculations for Risk or Prevalence Ratios and Differences
Spiegelman, D. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi188 · Cited by 1,738
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Ranibizumab for Diabetic Macular Edema
Nguyen, Q. D., Brown, D. M., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Gibson, A., Sy, J., Rundle, A. C., Hopkins, J. J., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.039 · Cited by 1,621
Elman, M. J., Aiello, L. P., Beck, R. W., Bressler, N. M., Bressler, S. B., Edwards, A. R., Ferris, F. L., Friedman, S. M., Glassman, A. R., Miller, K. M., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.031 · Cited by 1,428
Mitchell, P., Bandello, F., Schmidt-Erfurth, U., Lang, G. E., Massin, P., Schlingemann, R. O., Sutter, F., Simader, C., Burian, G., Gerstner, O., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.031 · Cited by 1,326
Brown, D. M., Nguyen, Q. D., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Schlottmann, P. G., Rundle, A. C., Zhang, J., Rubio, R. G., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.02.034 · Cited by 830
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
Schmidt-Erfurth, U., Kaiser, P. K., Korobelnik, J.-F., Brown, D. M., Chong, V., Nguyen, Q. D., Ho, A. C., Ogura, Y., Simader, C., Jaffe, G. J., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.011 · Cited by 822
Intravitreal Aflibercept for Diabetic Macular Edema
Korobelnik, J.-F., Do, D. V., Schmidt-Erfurth, U., Boyer, D. S., Holz, F. G., Heier, J. S., Midena, E., Kaiser, P. K., Terasaki, H., Marcus, D. M., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.006 · Cited by 816
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Culliford, L. A., & Reeves, B. C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61501-9 · Cited by 748
Antonetti, D. A., Barber, A. J., Hollinger, L. A., Wolpert, E. B., & Gardner, T. W. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23463 · Cited by 686
A computerized method of visual acuity testing
Beck, R. W., Moke, P. S., Turpin, A. H., Ferris, F. L., SanGiovanni, J. P., Johnson, C. A., Birch, E. E., Chandler, D. L., Cox, T. A., Blair, R. C., et al. (2003) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01825-1 · Cited by 607
Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study
Nguyen, Q. D., Shah, S. M., Khwaja, A. A., Channa, R., Hatef, E., Do, D. V., Boyer, D., Heier, J. S., Abraham, P., Thach, A. B., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.08.016 · Cited by 532
Michaelides, M., Kaines, A., Hamilton, R. D., Fraser-Bell, S., Rajendram, R., Quhill, F., Boos, C. J., Xing, W., Egan, C., Peto, T., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.03.045 · Cited by 521
A Phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular Edema
(2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.05.062 · Cited by 451
Prevalence of and Risk Factors for Diabetic Macular Edema in the United States
Varma, R., Bressler, N. M., Doan, Q. V., Gleeson, M., Danese, M., Bower, J. K., Selvin, E., Dolan, C., Fine, J., Colman, S., et al. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.2854 · Cited by 423
Rajendram, R., Fraser-Bell, S., Kaines, A., Michaelides, M., Hamilton, R. D., Esposti, S. D., Peto, T., Egan, C., Bunce, C., Leslie, R. D., et al. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2012.393 · Cited by 389
One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema
Do, D. V., Nguyen, Q. D., Boyer, D., Schmidt-Erfurth, U., Brown, D. M., Vitti, R., Berliner, A. J., Gao, B., Zeitz, O., Ruckert, R., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.010 · Cited by 385
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Moja, L., Lucenteforte, E., Kwag, K. H., Bertele, V., Campomori, A., Chakravarthy, U., D'Amico, R., Dickersin, K., Kodjikian, L., Lindsley, K., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011230.pub2 · Cited by 187
Anti-vascular endothelial growth factor for diabetic macular oedema
Virgili, G., Parravano, M., Menchini, F., & Evans, J. R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007419.pub4 · Cited by 184
Thulliez, M., Angoulvant, D., Lez, M. L., Jonville‐Béra, A. ‐., Pisella, P., Gueyffier, F., & Bejan‐Angoulvant, T. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.2333 · Cited by 135
Bressler, S. B., Edwards, A. R., Chalam, K. V., Bressler, N. M., Glassman, A. R., Jaffe, G. J., Melia, M., Saggau, D. D., & Plous, O. Z. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.1698 · Cited by 108
for the Pan-American Collaborative Retina Study Group (PACORES), Arévalo, J. F., Sánchez, J. G., Fromow-Guerra, J., Wu, L., Berrocal, M. H., Farah, M. E., Cardillo, J. A., & Rodríguez, F. J. (2009) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-008-1034-x · Cited by 93
Bressler, N. M., Boyer, D. S., Williams, D. F., Butler, S. M., Francom, S. F., Brown, B., Nucci, F. D., Cramm, T., Tuomi, L. L., Ianchulev, T., et al. (2012) · Retina · doi:10.1097/iae.0b013e31825db6ba · Cited by 89
Resource Use and Costs Associated With Diabetic Macular Edema in Elderly Persons
Shea, A. M. (2008) · Archives of Ophthalmology · doi:10.1001/archopht.126.12.1748 · Cited by 86
Evaluation of Compounded Bevacizumab Prepared for Intravitreal Injection
Yannuzzi, N. A., Klufas, M. A., Quach, L., Beatty, L. M., Kaminsky, S. M., Crystal, R. G., D’Amico, D. J., & Kiss, S. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.3591 · Cited by 60
Lasting Controversy on Ranibizumab and Bevacizumab
Zou, L., Lai, H.-Y., Zhou, Q., & Xiao, F. (2011) · Theranostics · doi:10.7150/thno/v01p0395 · Cited by 37
More on influenza vaccine in young children.
Sancho, A., Melchiorri, D., & Abadie, E. (2012) · PubMed · doi:10.1056/nejmc1205643 · Cited by 22
Research works printed but not linked: 4
- 10.1097/IAE.0b013e3182695b83 · doi:10.1097/iae.0b013e3182695b83
- 10.1191/096228099671525676 · DOI
- Virgili G, 2014, Cochrane Database Syst Rev, 10, CD007419
- Moja L, 2014, Cochrane Database Syst Rev, 9, CD011230
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Abràmoff, M. D., Lavin, P. T., Birch, M., Shah, N., & Folk, J. C. (2018) · npj Digital Medicine · doi:10.1038/s41746-018-0040-6 · Cited by 1,638
Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss
Lee, R., Wong, T. Y., & Sabanayagam, C. (2015) · Eye and Vision · doi:10.1186/s40662-015-0026-2 · Cited by 1,569
Diabetic Retinopathy: Pathophysiology and Treatments
Wang, W., & Lo, A. C. Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061816 · Cited by 1,358
Wong, T. Y., Cheung, C. M. G., Larsen, M., Sharma, S., & Simó, R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.12 · Cited by 1,094
Metadata
- Authors
- The Diabetic Retinopathy Clinical Research Network
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-03-26
- Volume
- 372
- Issue
- 13
- Pages
- 1193-1203
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1786299986
- Cited by
- 1,607
- References
- 35
- FWCI
- 160.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.